肠道菌群成为帕金森病治疗的新靶点

Intestinal Flora: A New Target for the Treatment of Parkinson’s Disease

帕金森病是一种受遗传和环境因素影响的神经退行性疾病,其发病机制尚不清晰。与健康人相比,帕金森患者的肠道菌群发生紊乱,具体表现为肠道微生物丰度的提高以及特定菌属的增加。益生菌可以通过调节肠道菌群有效改善帕金森患者的机体炎症、便秘和腹痛等症状,提高患者的生活质量。基于这些特性,益生菌有望成为帕金森病治疗的一种辅助手段应用到实际生活中。本文从帕金森患者的肠道菌群、病程和治疗方法等方面出发,根据近几年的研究报告进行综述,总结了帕金森患者的肠道菌群特点及二者间的联系,并对益生菌干预的新型治疗方法进行讨论,为帕金森病的治疗提供新的参考。

Parkinson’s disease(PD) is a neurodegenerative disease influenced by genetic and environmental factors, and its pathogenesis is still unclear. Compared with healthy people, the intestinal flora of patients with PD is disturbed, which is manifested by an increase in the abundance of intestinal microbial and an increase in specific bacteria. Probiotics can effectively improve the quality of PD patients’ life by regulating the intestinal flora and improving symptoms such as inflammation, constipation and abdominal pain. Based on these properties, probiotics are expected to become an adjunct to the treatment of Parkinson’s disease in real life. Starting from the aspects of intestinal flora, disease course and treatment methods of Parkinson’s patients, this paper reviews the research reports in recent years. Moreover, this paper summarizes the characteristics of intestinal flora of Parkinson’s patients and the relationship between them, and discusses the new therapeutic methods of probiotic intervention, which provides a new reference for the treatment of Parkinson’s disease.